FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Singulair | Drug Marketing | Merck

Can Merck boost Singulair sales?

Tools

One of the shining stars over at Merck has been Singulair, the allergy and asthma med that pulled in some $4.4 billion last year. Well, for the most recent quarter, sales actually slipped by 1 percent as patients have defected to the new over-the-counter Zyrtec sold by Johnson & Johnson. Plus, the FDA's March announcement of a probe into a potential link between Singulair and suicidal behavior--and a fairly mild spring allergy season--didn't help. Merck acknowledged the flattening sales, lowering its forecast to a range of $4.4 billion to $4.6 billion from its previous estimate of $4.6 billion to $4.8 billion.

What can Merck do to turn it around? The company is offering $20 coupons for Singulair on its website, and it extended its spring ad campaign into the summer. "[W]e are taking additional steps to further support the brand," the company said late last month. Third-quarter sales figures will show just how successful those efforts turn out to be.

- read the story in CNN Money

Related Articles:
Analyst: Singulair drop threatens Merck
FDA interviews for Singulair psych effects
FDA nixes Merck, Schering allergy combo

Bookmark and Share
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about Singulair   Drug Marketing   Merck  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.